All enrolled people who been given a minimum of 1 dose of zosuquidar or placebo during induction have been monitored to the event of adverse occasions (439 patients, 219 on zosuquidar and 210 on placebo). The commonest adverse functions have been linked to the period of extended and considerable myelosuppression https://johnj665whr8.creacionblog.com/profile